Etravirine (TMC 125 )

Medical Advocates
Etravirine (Intelence/TMC125)

Main Page

New and Noteworthy

Expanded Access

FDA Approvals
Journal Citations
Conference Citations

Pediatric Indications
Product Information

Patient Information

ARV Drugs Main Page

Home Page

This web page is best viewed by using INTERNET EXPLORER
Last Update: June 20, 2008

Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader

New and Noteworthy

June 2008

CONFERENCE PDF POSTER
Determination of phenotypic clinical cut-offs for etravirine (ETR): pooled Week 24
results of the DUET-1 and DUET-2 trials
M Peeters, S Nijs, J Vingerhoets, et al 2008 International HIV Drug Resistance Workshop

CONFERENCE PDF POSTER
Nucleoside-associated mutations cause hypersusceptibility to etravirine (ETR)
G Picchio, J Vingerhoets, N Parkin, et al 2008 International HIV Drug Resistance Workshop

CONFERENCE PDF POSTER
An update of the list of NNRTI mutations associated with decreased virologic response to
etravirine (ETR): multivariate analyses on the pooled DUET-1 and DUET-2 clinical trial data
J Vingerhoets, M Peeters, H Azijn, et al 2008 International HIV Drug Resistance Workshop

CONFERENCE POWERPOINT PRESENTATION
Pooled 48-Week Analysis of DUET-1 and DUET-2: Durable Efficacy and Safety Results of Etravirine (ETR; TMC125) in
Treatment-Experienced HIV-infected Patients
A Cheret, C Katlama, B Trottier, et al ISHEID 2008

May 2008

A pharmacokinetic study of etravirine (TMC125) co-administered with ranitidine and omeprazole in HIV-volunteers.
Schöller-Gyüre M, Kakuda TN, De Smedt G, et al Br J Clin Pharmacol. 2008 May 19

Is there a role for etravirine in patients with Nonnucleoside reverse transcriptase inhibitor
resistance?
Scott C, Grover D, Nelson M. AIDS. 2008 May 11;22(8):989-90.

Expanded Access

FULL-TEXT DOCUMENT
Tibotec Announces Expanded Access Program for TMC125
Tibotec
September 25, 2006
News Release

FDA Approvals

A WEEK-IN-REVIEW FEATURED REPORT
FULL-TEXT DOCUMENT
FDA Grants Accelerated Approval for Etravirine.
FDA
January 18, 2007
News Release

Pediatric Indications

POSTER
Pharmacokinetics of the Next-generation NNRTI TMC125 in HIV-infected Children between 6 and
17 Years of Age
T Kakuda, C Konigs, C Feiterna-Sperling, et al
PDF Poster Abstract

ARV Drugs Main Page Home Page

Etravirine Main Page